Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), the Leukemia and Lymphoma Society, Translational Research Program (2021), and the Alan Steinrberg Award (2022). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.
Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), the Leukemia and Lymphoma Society, Translational Research Program (2021), and the Alan Steinrberg Award (2022). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.